Abstract
MIL60 is a biosimilar of bevacizumab (BEV) which can bind and inhibit vascular endothelial growth factor. We compared the efficacy, safety, popular pharmacokinetics (PoP PK) and immunogenicity of MIL60 with BEV in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.